Nasally delivered SARS-CoV-2 vaccines: future promise and challenges

This publication has 10 references indexed in Scilit:

• Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
  The Lancet Respiratory Medicine, 2023
• Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial
  The Lancet Infectious Diseases, 2023
• A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
  Vaccines, 2023
• Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
  The Lancet Respiratory Medicine, 2022
• Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial
  The Lancet Respiratory Medicine, 2022
• Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
  New England Journal of Medicine, 2022
• Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants
  New England Journal of Medicine, 2022
• Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
  The Lancet Infectious Diseases, 2021
• Comparative Efficacy of Inactivated and Live Attenuated Influenza Vaccines
  New England Journal of Medicine, 2009
• Live Attenuated versus Inactivated Influenza Vaccine in Infants and Young Children
  New England Journal of Medicine, 2007